MRT-2359
MYC-driven solid tumors and lymphomas
Key Facts
Indication
MYC-driven solid tumors and lymphomas
Phase
Phase 1/2
Status
Active, Recruiting
Company
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is leveraging its proprietary QuEEN™ discovery engine to create a new class of small molecule medicines called molecular glue degraders, which harness the body's natural protein degradation machinery to eliminate specific disease-driving proteins. The company's lead program, MRT-2359, is a potent, selective degrader of GSPT1 and is being evaluated in a Phase 1/2 trial for MYC-driven solid tumors and lymphomas. With a strong leadership team, strategic partnerships, and a deep pipeline of preclinical programs, Monte Rosa aims to address significant unmet medical needs in oncology and beyond by targeting proteins that have historically been considered undruggable.
View full company profile